Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

NASDAQ:XLO

Overview | Financials
Company Name Xilio Therapeutics, Inc.
Symbol XLO
Currency USD
Price 1.11
Market Cap 48,793,461
Dividend Yield 0%
52-week-range 0.5 - 1.93
Industry Biotechnology
Sector Healthcare
CEO Dr. Rene Russo BCPS, Pharm.D, Pharm.D.
Website https://www.xiliotx.com

An error occurred while fetching data.

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a

Related Stocks

Adverum Biotechnologies, Inc. logo

Adverum Biotechnologies, Inc.

ADVM

4.74 USD

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

0.838 USD

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

0.775 USD

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

ALZN

1.15 USD

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

14.13 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

2.03 USD

Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc.

PBYI

2.81 USD

PAVmed Inc. logo

PAVmed Inc.

PAVM

0.645 USD

Financials

Numbers are in millions USD

Numbers are in millions USD